Oncimmune Holdings PLC PDMR Dealing (0850J)

TIDMONC

RNS Number : 0850J

Oncimmune Holdings PLC

18 December 2020

Oncimmune Holdings plc

("Oncimmune" or the "Company")

PDMR Dealing

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, has been notified that Adam Hill, PDMR and Chief Executive Officer, has purchased 5,764 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") for GBP1.7348 per share on 17 December 2020.

Following this transaction, Adam has a total interest in the Company of 3,537,539 Ordinary Shares, representing approximately 5.6 per cent of the Company's issued Ordinary Share capital.

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 
       Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                  Dr Adam Mark Hill 
      ------------------------------------  -------------------------------------- 
 2     Reason for the notification 
      ---------------------------------------------------------------------------- 
 a)    Position/status                       Chief Executive Officer 
      ------------------------------------  -------------------------------------- 
 b)    Initial notification                  Initial notification 
        /Amendment 
      ------------------------------------  -------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ---------------------------------------------------------------------------- 
 a)    Name                                  Oncimmune Holdings plc 
      ------------------------------------  -------------------------------------- 
 b)    LEI                                   213800HCYIWT6YPI1I02 
      ------------------------------------  -------------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      ---------------------------------------------------------------------------- 
 a)    Description                           Ordinary Shares of GBP0.01 each 
        of the financial 
        instrument, 
        type of instrument 
 
       Identification                        ISIN: GB00BYQ94H38 
        code 
 
 b)    Nature of                             Purchase of shares 
        the transaction 
      ------------------------------------  -------------------------------------- 
 c)    Price(s) 
        and volume(s) 
                                             --------------------  ------------- 
                                              Price                 Volume 
                                             --------------------  ------------- 
    GBP1.7348                                                       5,764 
   --------------------------------------------------------------  ------------- 
 
 d)    Aggregated 
        information 
 
  - Aggregated                          Same as above 
   volume 
 
  - Price 
 
 e)    Date of the                           17 December 2020 
        transaction 
      ------------------------------------  -------------------------------------- 
 f)    Place of                              London stock exchange, AIM 
        the transaction 
      ------------------------------------  -------------------------------------- 
 

For further information:

Oncimmune Holdings plc

Ron Kirschner, General Counsel and Company Secretary

[e-mail]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHKKOBNFBDDPBD

(END) Dow Jones Newswires

December 18, 2020 02:00 ET (07:00 GMT)